SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: William Partmann who wrote (764)12/16/1999 10:51:00 AM
From: tewdwr  Read Replies (1) | Respond to of 10345
 
Anyone care to offer insight into the value of the ISIP (ISIS Pharma)warrants, in return for a cash infusion from ELN, announced in May 99?

ISIP blew up yesterday on failure of its Crohns disease ISIS-2302 compound. They also have a contract with ELN to develop an oral dosing formulation for large molecule ISIS-2302 and anti-sense compounds.

Does anyone think either could substantially impact ELN's financials going forward, i.e.-lower earnings projections?



To: William Partmann who wrote (764)12/16/1999 11:33:00 AM
From: All Mtn Ski  Read Replies (1) | Respond to of 10345
 
Looks like ELN has had some year end tax selling...

I have decided to add more shares. My dumb move on the calls has made the first purchase date I can get back in on Monday. Hopefully ELN won't rally too much until then! With this move ELN will be my 2nd largest holding.

The fundamentals are just too strong to deny.

Tom


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News